Results 201 to 210 of about 11,287 (253)
Some of the next articles are maybe not open access.
The radioimmunoassay of buprenorphine
European Journal of Clinical Pharmacology, 1980Antisera to buprenorphine were obtained in rabbits immunised with 3-0-carboxymethylbuprenorphine and N-hemisuccinyl-norbuprenorphine conjugated to bovine serum albumin. Using the latter antiserum and tritium labelled buprenorphine a radioimmunoassay have good accuracy and precision was developed for concentrations as low as 50 picograms in 1 ml of ...
A J, Bartlett +6 more
openaire +2 more sources
Drugs, 2003
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia
Drug and Alcohol Dependence, 2010Buprenorphine maintenance is efficacious for treating opioid dependence, but problems with diversion and misuse of buprenorphine (BUP) may limit its acceptability and dissemination. The buprenorphine/naloxone combination tablet (BNX) was developed to reduce potential problems with diversion and abuse.
B, Vicknasingam +3 more
openaire +2 more sources
Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
Psychopharmacology, 2001Buprenorphine is an opioid agonist-antagonist used in the treatment of opioid dependence. Naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine. This addition of naloxone may also confer further opioid blockade efficacy.To test the opioid blockade efficacy of sublingual buprenorphine/naloxone versus ...
Eric C, Strain +2 more
openaire +2 more sources
Journal of Opioid Management, 2018
A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
openaire +2 more sources
A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
openaire +2 more sources
Journal of the American Academy of Child & Adolescent Psychiatry, 2023
Paul E.A. Glaser +3 more
openaire +1 more source
Paul E.A. Glaser +3 more
openaire +1 more source
Buprenorphine, Buprenorphine/Naloxone (Suboxone)
2023William F. Barrett, Carey Brewbaker
openaire +1 more source